^
Association details:
| Biomarker: | BRCA wild-type |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | carboplatin (Tubulin polymerization promoter) + paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) + cyclophosphamide (Alkylating agent) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P118 Efficacy of platinum-based neoadjuvant chemotherapy in early triple-negative breast cancer according to germline BRCA mutation
Published date:
03/16/2023
Excerpt:
...platinum-based chemotherapy (carboplatin AUC 5 or 6 every 3 weeks × 4/paclitaxel weekly × 12 + anthracycline/cyclophosphamide...Among the patients with BRCAwild type, the pCR rate was significantly higher in platinum-based chemotherapy than in non-platinum-based chemotherapy (56.7% vs. 29.2%, p = 0.001)...Unexpectedly, our results showed that platinumbased chemotherapy was more effective in gBRCA-wild type TNBC.
